---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-080021"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:49:39.566488+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PepGen appoints Afsaneh Mohebbi, Ph.D. as SVP Portfolio & Program Mgmt and Dave Borah, CFA as SVP IR & Corp Comms

## Summary
- Afsaneh Mohebbi, Ph.D. appointed SVP, Portfolio & Program Management; previously consultant to PepGen since Jan 2024.
- Dave Borah, CFA named SVP, Investor Relations & Corporate Communications; most recently SVP at Mural Oncology.
- Appointments effective immediately; CEO cites expertise as key ahead of clinical milestones in H2 2024.
- Mohebbi led Fabry drug Replagal and Firazyr approvals at Shire; Borah increased analyst coverage at Bicycle Therapeutics.

## SEC filing metadata
- accession: 0000950170-24-080021
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/0000950170-24-080021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024080021/pepg-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-080021
- JSON: https://secwatch.observer/filing/0000950170-24-080021.json
- Plain text: https://secwatch.observer/filing/0000950170-24-080021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.